Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073661 | 0.88 | TSHR (0.51) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL27962250 | 0.86 | TSHR (0.38) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL12047219 | 0.83 | TSHR (0.36) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL25699072 | 0.83 | KMT2A (0.41) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL3473691 | 0.82 | TSHR (0.41) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL7479511 | 0.82 | NAAA (0.46) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL10164226 | 0.82 | KMT2A (0.37) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL185586 | 0.81 | EPHX2 (0.39) | — | |
| SCHEMBL12047216 | 0.81 | EPHX2 (0.39) | — | |
| SCHEMBL22699687 | 0.81 | EPHX2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748666-B2 | Preparation methods of methyl-D3-amine and salts thereof | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-06-10 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471031-B2 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249401-A1 | Process for the preparation of sterically hindered nitroxyl ethers | PPOX, CBR1, CBR3 | TSHR 3332/4885KMT2A 2110/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.